Alzheimer's Disease INSIGHTS

Alzheimer's Treatment Decreases Plaques, Improves Cognition

photo from Alzheimer's Treatment Decreases Plaques, Improves Cognition

Researchers at Biogen published a pivotal Phase 1b clinical study of an Alzheimer's treatment showing not only a decrease in plaques when the monoclonal antibody aducanumab is administered, but also some cognitive improvement in humans. From the paper: "Antibody-based immunotherapy against Αβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that...  Read More

Cancer Drug Suggests Promising Alzheimer's Treatment

photo from Cancer Drug Suggests Promising Alzheimer's Treatment

In a 2015 report, a team of scientist from the Weizmann Institute of Science provided compelling evidence that boosting the immune response in the brain (as opposed to suppressing it) might be a promising avenue for Alzheimer's research. In an extension of its initial findings, the team found that inhibiting an immune-checkpoint pathway which is targeted in the treatment of certain forms of cancer dramatically reduces Alzheimer's...  Read More

Mouse Model Helps Accelerate Development of New Alzheimer's Therapies

photo from Mouse Model Helps Accelerate Development of New Alzheimer's Therapies

The majority of the drugs approved by the FDA for treatment of cognitive symptoms in Alzheimer's disease (AD) patients are cholinesterase inhibitors and include drugs such as donepezil, galantamine, and rivastagimine. However, the tolerated doses of cholinesterase inhibitors, such as donepezil, produce only partial improvement in memory and can have severe GI side effects. Since these medications have to be taken for prolonged durations, the limited efficacy...  Read More